18:07 , May 19, 2017 |  BioCentury  |  Finance

Breathe in, cash out

By installing a proven CEO and ponying up sufficient cash to clear Phase II development, Genoa Pharmaceuticals Inc.’s investors believe the company is primed to reach value inflection. Genoa raised $62 million in a series A...
22:48 , May 15, 2017 |  BC Extra  |  Financial News

Genoa's series A brings in $62M

Pulmonary play Genoa Pharmaceuticals Inc. (Seattle, Wash.) said it raised $62 million in a series A financing led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners. Also participating were Novo A/S (Hellerup, Denmark),...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

GP-101 regulatory update

Genoa said FDA granted Orphan Drug designation to the company’s inhaled GP-101 - an aerosol formulation of pirfenidone - to treat idiopathic pulmonary fibrosis (IPF). The company expects clinical trials of GP-101 to begin early...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Genoa Pharmaceuticals preclinical data

In an animal model of IPF, small inhaled doses of GP-101 produced high peak, short duration lung pirfenidone concentrations with significantly greater anti-fibrotic efficacy vs. higher oral doses of pirfenidone, which led to low peak...